BetterLife Pharma has appointed Professor Richard B. Lipton, MD, as Co-Chair of its Scientific Advisory Board alongside Professor Peter Goadsby to guide the development of BETR-001, a drug candidate for chronic cluster headache and migraine. Dr. Lipton is a leading expert in headache research and brings extensive experience in clinical trials and epidemiology, complementing Dr. Goadsby's biological expertise. This leadership strengthens BetterLife's scientific oversight as it advances BETR-001 toward clinical trials. The company also granted Dr. Lipton stock options as part of his appointment.
BetterLife Pharma's appointment of Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board provides context for readers following health sector developments. For readers following health sector stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:01 WIB: out of 150 priced US health-sector stocks tradable on Pluang, 73 rose and 47 fell today. Notable movers include CGC at USD 0.72 with a 1-day change of +1.68% and a typical hold time of 39 days, IONS at USD 43.60 with a 1-day change of +1.54% and a typical hold time of 4 days, and ABCL at USD 11.98 with a 1-day change of +1.53% and a typical hold time of 41 days.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
